View ValuationKissei Pharmaceutical 将来の成長Future 基準チェック /06Kissei Pharmaceutical利益と収益がそれぞれ年間0.3%と3.9%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に6.3% 3.5%なると予測されています。主要情報0.3%収益成長率3.53%EPS成長率Pharmaceuticals 収益成長14.5%収益成長率3.9%将来の株主資本利益率6.27%アナリストカバレッジGood最終更新日22 May 2026今後の成長に関する最新情報お知らせ • Oct 29Kissei Pharmaceutical Co., Ltd. Revises Consolidated Earnings Guidance for the First Half Ending September 30, 2023Kissei Pharmaceutical Co., Ltd. revised consolidated earnings guidance for the first half ending September 30, 2023. For the first half ending September 30, 2022, the company expects net sales of JPY 36,900 million compared to previous guidance of JPY 35,500 million, operating profit of JPY 2,000 million compared to previous guidance of JPY 900 million, profit attributable to owners of parent of JPY 5,600 million compared to previous guidance of JPY 4,800 million and basic earnings per share of JPY 122.26 per share compared to previous guidance of JPY 104.09.すべての更新を表示Recent updatesお知らせ • May 13Kissei Pharmaceutical Co., Ltd. (TSE:4547) announces an Equity Buyback for 1,300,000 shares, representing 3.14% for ¥6,000 million.Kissei Pharmaceutical Co., Ltd. (TSE:4547) announces a share repurchase program. Under the program, the company will repurchase up to 1,300,000 shares, representing 3.14% of its share capital, for ¥ 6,000 million. The company will repurchase its shares in order to implement a flexible capital policy which responds to changes in the business environment, improve capital efficiency, and enhance shareholder returns. The shares repurchased will be cancelled. The program is valid till December 31, 2026. As of April 30, 2026, the company had 41,451,945 shares outstanding (excluding treasury shares) and 5,090,040 shares in treasury.お知らせ • May 11Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2026Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2026.お知らせ • May 09Kissei Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 11, 2026Kissei Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 11, 2026お知らせ • Dec 02Kissei Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Jan 30, 2026Kissei Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Jan 30, 2026お知らせ • Sep 02Kissei Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Nov 04, 2025Kissei Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results on Nov 04, 2025お知らせ • Jun 03Kissei Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Jul 29, 2025Kissei Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Jul 29, 2025お知らせ • May 08Kissei Pharmaceutical Co., Ltd. (TSE:4547) announces an Equity Buyback for 1,400,000 shares, representing 3.27% for ¥5,334 million.Kissei Pharmaceutical Co., Ltd. (TSE:4547) announces a share repurchase program. Under the program, the company will repurchase up to 1,400,000 shares, representing 3.27% of its share capital, for ¥ 5,334 million. The shares will be repurchased at price of ¥ 3,810 per share. The company will repurchase its shares in order to implement a flexible capital policy which responds to changes in the business environment, improve capital efficiency, and enhance shareholder returns. The shares repurchased will be cancelled. As of April 30, 2025, the company had 42,805,038 shares outstanding (excluding treasury shares) and 5,106,147 shares in treasury.お知らせ • May 07Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 24, 2025Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 24, 2025.お知らせ • Mar 01Kissei Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on May 07, 2025Kissei Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 07, 2025お知らせ • Feb 26Kissei Pharmaceutical Co., Ltd. Announces Submission of New Drug Application for Gnhh Antagonist "Linzagolix" Indicated for Uterine Fibroids, in JapanKissei Pharmaceutical Co., Ltd. announced that the company has submitted a new drug application for approval of manufacturing and marketing in Japan for the GnRH antagonist "Linzagolix" as indicated for uterine fibroids. Linzagolix is an orally administered GnRH (gonadotropin-releasing hormone)receptor antagonist. It antagonizes GnRH at the GnRH receptors located in the pituitary gland, thereby inhibiting the secretion of gonadotropins, which are gonadal-stimulating hormones. This reduction in gonadotropin secretion leads to a decrease in estrogen production in the ovaries, thereby improving bleeding and pain symptoms in patients with uterine fibroids. In two domestic phase III clinical trials (KLH2301 and KLH2302 trials) targeting uterine fibroids, Linzagolix demonstrated non-inferiority and superiority to the control group, respectively, and yielded favorable results. In Japan, Kissei is preparing for a domestic Phase III clinical trial for endometriosis. Overseas, Theramex (UK), licensee, is set to launch the drug for uterine fibroids in Europe in September 2024, and received approval from the European Medicines Agency (EMA) for the additional indication of endometriosis in November of the same year. Additionally, other licensee companies are progressing with development in South Korea and Taiwan. Kissei is committed to making Linzagolix available to patients worldwide as soon as possible.お知らせ • Nov 30Kissei Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 03, 2025Kissei Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Feb 03, 2025お知らせ • Nov 05Kissei Pharmaceutical Co., Ltd. (TSE:4547) announces an Equity Buyback for 1,400,000 shares, representing 3.17% for ¥5,292 million.Kissei Pharmaceutical Co., Ltd. (TSE:4547) announces a share repurchase program. Under the program, the company will repurchase up to 1,400,000 shares, representing 3.17% of its share capital, for ¥ 5,292 million. The shares will be repurchased at price of ¥ 3,780 per share. The company will repurchase its shares in order to implement a flexible capital policy which responds to changes in the business environment, improve capital efficiency, and enhance shareholder returns. The shares repurchased will be cancelled. As of October 31, 2024, the company had 44,205,187 shares outstanding (excluding treasury shares) and 5,105,998 shares in treasury.お知らせ • Sep 09Kissei Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 05, 2024Kissei Pharmaceutical Co., Ltd. announced that they will report Q2, 2025 results on Nov 05, 2024お知らせ • Jun 28Kissei Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Jul 30, 2024Kissei Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Jul 30, 2024お知らせ • May 08Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024.お知らせ • Mar 13Kissei Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 07, 2024Kissei Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results on May 07, 2024お知らせ • Jan 30Kissei Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 2024Kissei Pharmaceutical Co., Ltd. provided dividend guidance for the year ending March 2024. For the period, Company expects dividend of JPY 41.00 per share against JPY 40.00 per share paid a year ago.お知らせ • Dec 12Kissei Pharmaceutical Co., Ltd. and Maruishi Pharmaceutical Co., Ltd. Announces KORSUVA®? IV Injection Syringe for Dialysis 17.5ug, 25.0ug to Launch in Japan for Treatment of Pruritus in Patients Undergoing HemodialysisKissei Pharmaceutical Co., Ltd. and Maruishi Pharmaceutical Co., Ltd. announced that KORSUVA® IV Injection Syringe for Dialysis 17.5g, 25.0g, and 35.0g (generic name: difelikefalin acetate "KORSUVA®") for the treatment of pruritus in patients undergoing hemodialysis will launch in Japan on December 13, 2023. KORSUVA® is a kappa opioid receptor agonist originated and developed by Cara Therapeutics Inc. In April 2013, Maruishi acquired certain rights from Cara, and since March 2017, Maruishi and Kissei have been jointly developing KORSUVA® for the indication of uremic pruritus in Japan. On September 25, 2023, Maruishi obtained manufacturing and marketing authorization of KORSUVA® in Japan for the treatment of pruritus in patients undergoing hemodialysis. The product is manufactured by Maruishi and marketed by Kissei in Japan. KORSUVA® is provided as a pre-filled syringe formulation to facilitate convenience in the medical environment. Through the supply of KORSUVA® Kissei and Maruishi strive to expand treatment options for uremic pruritus and to improve the QOL (Quality of Life) of patients undergoing hemodialysis.お知らせ • Dec 07Kissei Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Jan 30, 2024Kissei Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Jan 30, 2024お知らせ • Oct 29Kissei Pharmaceutical Co., Ltd. Revises Consolidated Earnings Guidance for the First Half Ending September 30, 2023Kissei Pharmaceutical Co., Ltd. revised consolidated earnings guidance for the first half ending September 30, 2023. For the first half ending September 30, 2022, the company expects net sales of JPY 36,900 million compared to previous guidance of JPY 35,500 million, operating profit of JPY 2,000 million compared to previous guidance of JPY 900 million, profit attributable to owners of parent of JPY 5,600 million compared to previous guidance of JPY 4,800 million and basic earnings per share of JPY 122.26 per share compared to previous guidance of JPY 104.09.お知らせ • Aug 30Kissei Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 07, 2023Kissei Pharmaceutical Co., Ltd. announced that they will report Q2, 2024 results on Nov 07, 2023お知らせ • Jul 21Kissei Pharmaceutical Co., Ltd. Announces Withdrawal of Application for Marketing Approval for Rovatirelin for the Treatment of Spinocerebellar Degeneration in JapanKissei Pharmaceutical Co., Ltd. announced the withdrawal of application for marketing approval in Japan for Rovatirelin (generic name, development number: KPS-0373), a treatment for spinocerebellar degeneration, in order to consider the future development strategies. Based on the results of two Phase III clinical trials and a combined analysis conducted to date, company determined that Rovatirelin was the first drug which has been verified to be effective to improve ataxia in patients with spinocerebellar degeneration assessed with international SARA score. The company submitted an application for marketing approval on December 22, 2021*. However, Kissei decided to temporarily withdraw the application for marketing approval and discuss the possibility of conducting additional clinical trials with the Pharmaceuticals and Medical Devices Agency (PMDA), because the PMDA has recently expressed its opinion that the marketing approval based on the current clinical trial data would be difficult. The impact of this matter on this fiscal year's business performance is minimal. If any matters requiring disclosure arise in the future, they will be promptly announced.お知らせ • May 28Kissei Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023Kissei Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on Jul 31, 2023お知らせ • May 10Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 22, 2023Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 22, 2023.お知らせ • May 09+ 2 more updatesKissei Pharmaceutical Co., Ltd. (TSE:4547) announces an Equity Buyback for 2,000,000 shares, representing 4.34% for ¥6,000 million.Kissei Pharmaceutical Co., Ltd. (TSE:4547) announces a share repurchase program. Under the program, the company will repurchase up to 2,000,000 shares, representing 4.34% of its share capital, for ¥6,000 million. The company will repurchase its shares in order to implement a flexible capital policy which responds to changes in the business environment, improve capital efficiency, and enhance shareholder returns. The repurchase plan will be valid till March 29, 2024 . As of March 31, 2023, the company had 46,115,567 shares outstanding (excluding treasury shares) and 5,695,618 shares in treasury.お知らせ • Feb 01+ 1 more updateKissei Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023Kissei Pharmaceutical Co., Ltd. provided dividend guidance for the fiscal year ending March 31, 2023. For the year, the company expects to pay dividend of JPY 40.00 per share against JPY 28.00 per share paid a year ago.お知らせ • Nov 27Kissei Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Jan 31, 2023Kissei Pharmaceutical Co., Ltd. announced that they will report Q3, 2023 results on Jan 31, 2023お知らせ • Mar 05Kissei Pharmaceutical Co., Ltd. to Report Fiscal Year 2021 Results on May 11, 2021Kissei Pharmaceutical Co., Ltd. announced that they will report fiscal year 2021 results on May 11, 2021お知らせ • Nov 29Kissei Pharmaceutical Co., Ltd. to Report Q3, 2021 Results on Feb 01, 2021Kissei Pharmaceutical Co., Ltd. announced that they will report Q3, 2021 results on Feb 01, 2021お知らせ • Oct 04Kissei Pharmaceutical Co., Ltd. to Report Q2, 2021 Results on Nov 15, 2020Kissei Pharmaceutical Co., Ltd. announced that they will report Q2, 2021 results on Nov 15, 2020業績と収益の成長予測OTCPK:KSPH.F - アナリストの将来予測と過去の財務データ ( )JPY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2029107,59012,1128,99611,42063/31/2028103,19911,8458,06110,15463/31/202796,60710,49110,27310,90863/31/202697,40613,779-7,121-1,485N/A12/31/202595,29414,135N/AN/AN/A9/30/202591,69514,4965,53211,733N/A6/30/202589,35712,374N/AN/AN/A3/31/202588,33011,9611,4916,521N/A12/31/202483,38911,663N/AN/AN/A9/30/202481,06710,7312913,431N/A6/30/202477,43012,001N/AN/AN/A3/31/202475,57911,160-3,510-1,677N/A12/31/202373,71712,198N/AN/AN/A9/30/202371,60712,880-8,350-5,854N/A6/30/202370,52112,158N/AN/AN/A3/31/202367,49310,528-9,226-6,679N/A12/31/202266,93112,769N/AN/AN/A9/30/202265,85710,581-4,543-2,556N/A6/30/202265,03110,912N/AN/AN/A3/31/202265,38112,921-3861,533N/A12/31/202166,9345,664N/AN/AN/A9/30/202169,1486,555-2,042-349N/A6/30/202169,6187,204N/AN/AN/A3/31/202169,0445,285-4,027-2,542N/A12/31/202066,8775,715N/AN/AN/A9/30/202063,9705,063-573683N/A6/30/202063,1962,530N/AN/AN/A3/31/202063,2342,81712,63213,934N/A12/31/201965,5944,753N/AN/AN/A9/30/201968,1804,294N/A10,431N/A6/30/201970,5454,752N/AN/AN/A3/31/201972,2975,481N/A6,346N/A12/31/201872,4745,263N/AN/AN/A9/30/201873,0878,102N/A13,854N/A6/30/201873,0149,685N/AN/AN/A3/31/201874,0099,045N/A8,845N/A12/31/201773,8878,735N/AN/AN/A9/30/201772,4598,116N/A5,756N/A6/30/201771,3966,993N/AN/AN/A3/31/201771,7067,726N/A6,441N/A12/31/201672,1546,401N/AN/AN/A9/30/201673,5338,108N/A9,023N/A6/30/201673,7748,734N/AN/AN/A3/31/201671,2948,165N/A5,763N/A12/31/201571,2398,521N/AN/AN/A9/30/201569,0956,608N/A2,948N/A6/30/201570,9457,161N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: KSPH.Fの予測収益成長率 (年間0.3% ) は 貯蓄率 ( 3.5% ) を下回っています。収益対市場: KSPH.Fの収益 ( 0.3% ) US市場 ( 16.8% ) よりも低い成長が予測されています。高成長収益: KSPH.Fの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: KSPH.Fの収益 ( 3.9% ) US市場 ( 11.7% ) よりも低い成長が予測されています。高い収益成長: KSPH.Fの収益 ( 3.9% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: KSPH.Fの 自己資本利益率 は、3年後には低くなると予測されています ( 6.3 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日(UTC時間)企業分析2026/05/22 05:05終値2026/03/13 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Kissei Pharmaceutical Co., Ltd. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。16 アナリスト機関Ritsuo WatanabeBofA Global ResearchHidemaru YamaguchiCitigroup IncKazuaki HashiguchiDaiwa Securities Co. Ltd.13 その他のアナリストを表示
お知らせ • Oct 29Kissei Pharmaceutical Co., Ltd. Revises Consolidated Earnings Guidance for the First Half Ending September 30, 2023Kissei Pharmaceutical Co., Ltd. revised consolidated earnings guidance for the first half ending September 30, 2023. For the first half ending September 30, 2022, the company expects net sales of JPY 36,900 million compared to previous guidance of JPY 35,500 million, operating profit of JPY 2,000 million compared to previous guidance of JPY 900 million, profit attributable to owners of parent of JPY 5,600 million compared to previous guidance of JPY 4,800 million and basic earnings per share of JPY 122.26 per share compared to previous guidance of JPY 104.09.
お知らせ • May 13Kissei Pharmaceutical Co., Ltd. (TSE:4547) announces an Equity Buyback for 1,300,000 shares, representing 3.14% for ¥6,000 million.Kissei Pharmaceutical Co., Ltd. (TSE:4547) announces a share repurchase program. Under the program, the company will repurchase up to 1,300,000 shares, representing 3.14% of its share capital, for ¥ 6,000 million. The company will repurchase its shares in order to implement a flexible capital policy which responds to changes in the business environment, improve capital efficiency, and enhance shareholder returns. The shares repurchased will be cancelled. The program is valid till December 31, 2026. As of April 30, 2026, the company had 41,451,945 shares outstanding (excluding treasury shares) and 5,090,040 shares in treasury.
お知らせ • May 11Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2026Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2026.
お知らせ • May 09Kissei Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 11, 2026Kissei Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 11, 2026
お知らせ • Dec 02Kissei Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Jan 30, 2026Kissei Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Jan 30, 2026
お知らせ • Sep 02Kissei Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Nov 04, 2025Kissei Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results on Nov 04, 2025
お知らせ • Jun 03Kissei Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Jul 29, 2025Kissei Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Jul 29, 2025
お知らせ • May 08Kissei Pharmaceutical Co., Ltd. (TSE:4547) announces an Equity Buyback for 1,400,000 shares, representing 3.27% for ¥5,334 million.Kissei Pharmaceutical Co., Ltd. (TSE:4547) announces a share repurchase program. Under the program, the company will repurchase up to 1,400,000 shares, representing 3.27% of its share capital, for ¥ 5,334 million. The shares will be repurchased at price of ¥ 3,810 per share. The company will repurchase its shares in order to implement a flexible capital policy which responds to changes in the business environment, improve capital efficiency, and enhance shareholder returns. The shares repurchased will be cancelled. As of April 30, 2025, the company had 42,805,038 shares outstanding (excluding treasury shares) and 5,106,147 shares in treasury.
お知らせ • May 07Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 24, 2025Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 24, 2025.
お知らせ • Mar 01Kissei Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on May 07, 2025Kissei Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 07, 2025
お知らせ • Feb 26Kissei Pharmaceutical Co., Ltd. Announces Submission of New Drug Application for Gnhh Antagonist "Linzagolix" Indicated for Uterine Fibroids, in JapanKissei Pharmaceutical Co., Ltd. announced that the company has submitted a new drug application for approval of manufacturing and marketing in Japan for the GnRH antagonist "Linzagolix" as indicated for uterine fibroids. Linzagolix is an orally administered GnRH (gonadotropin-releasing hormone)receptor antagonist. It antagonizes GnRH at the GnRH receptors located in the pituitary gland, thereby inhibiting the secretion of gonadotropins, which are gonadal-stimulating hormones. This reduction in gonadotropin secretion leads to a decrease in estrogen production in the ovaries, thereby improving bleeding and pain symptoms in patients with uterine fibroids. In two domestic phase III clinical trials (KLH2301 and KLH2302 trials) targeting uterine fibroids, Linzagolix demonstrated non-inferiority and superiority to the control group, respectively, and yielded favorable results. In Japan, Kissei is preparing for a domestic Phase III clinical trial for endometriosis. Overseas, Theramex (UK), licensee, is set to launch the drug for uterine fibroids in Europe in September 2024, and received approval from the European Medicines Agency (EMA) for the additional indication of endometriosis in November of the same year. Additionally, other licensee companies are progressing with development in South Korea and Taiwan. Kissei is committed to making Linzagolix available to patients worldwide as soon as possible.
お知らせ • Nov 30Kissei Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 03, 2025Kissei Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Feb 03, 2025
お知らせ • Nov 05Kissei Pharmaceutical Co., Ltd. (TSE:4547) announces an Equity Buyback for 1,400,000 shares, representing 3.17% for ¥5,292 million.Kissei Pharmaceutical Co., Ltd. (TSE:4547) announces a share repurchase program. Under the program, the company will repurchase up to 1,400,000 shares, representing 3.17% of its share capital, for ¥ 5,292 million. The shares will be repurchased at price of ¥ 3,780 per share. The company will repurchase its shares in order to implement a flexible capital policy which responds to changes in the business environment, improve capital efficiency, and enhance shareholder returns. The shares repurchased will be cancelled. As of October 31, 2024, the company had 44,205,187 shares outstanding (excluding treasury shares) and 5,105,998 shares in treasury.
お知らせ • Sep 09Kissei Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 05, 2024Kissei Pharmaceutical Co., Ltd. announced that they will report Q2, 2025 results on Nov 05, 2024
お知らせ • Jun 28Kissei Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Jul 30, 2024Kissei Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Jul 30, 2024
お知らせ • May 08Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024.
お知らせ • Mar 13Kissei Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 07, 2024Kissei Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results on May 07, 2024
お知らせ • Jan 30Kissei Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 2024Kissei Pharmaceutical Co., Ltd. provided dividend guidance for the year ending March 2024. For the period, Company expects dividend of JPY 41.00 per share against JPY 40.00 per share paid a year ago.
お知らせ • Dec 12Kissei Pharmaceutical Co., Ltd. and Maruishi Pharmaceutical Co., Ltd. Announces KORSUVA®? IV Injection Syringe for Dialysis 17.5ug, 25.0ug to Launch in Japan for Treatment of Pruritus in Patients Undergoing HemodialysisKissei Pharmaceutical Co., Ltd. and Maruishi Pharmaceutical Co., Ltd. announced that KORSUVA® IV Injection Syringe for Dialysis 17.5g, 25.0g, and 35.0g (generic name: difelikefalin acetate "KORSUVA®") for the treatment of pruritus in patients undergoing hemodialysis will launch in Japan on December 13, 2023. KORSUVA® is a kappa opioid receptor agonist originated and developed by Cara Therapeutics Inc. In April 2013, Maruishi acquired certain rights from Cara, and since March 2017, Maruishi and Kissei have been jointly developing KORSUVA® for the indication of uremic pruritus in Japan. On September 25, 2023, Maruishi obtained manufacturing and marketing authorization of KORSUVA® in Japan for the treatment of pruritus in patients undergoing hemodialysis. The product is manufactured by Maruishi and marketed by Kissei in Japan. KORSUVA® is provided as a pre-filled syringe formulation to facilitate convenience in the medical environment. Through the supply of KORSUVA® Kissei and Maruishi strive to expand treatment options for uremic pruritus and to improve the QOL (Quality of Life) of patients undergoing hemodialysis.
お知らせ • Dec 07Kissei Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Jan 30, 2024Kissei Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Jan 30, 2024
お知らせ • Oct 29Kissei Pharmaceutical Co., Ltd. Revises Consolidated Earnings Guidance for the First Half Ending September 30, 2023Kissei Pharmaceutical Co., Ltd. revised consolidated earnings guidance for the first half ending September 30, 2023. For the first half ending September 30, 2022, the company expects net sales of JPY 36,900 million compared to previous guidance of JPY 35,500 million, operating profit of JPY 2,000 million compared to previous guidance of JPY 900 million, profit attributable to owners of parent of JPY 5,600 million compared to previous guidance of JPY 4,800 million and basic earnings per share of JPY 122.26 per share compared to previous guidance of JPY 104.09.
お知らせ • Aug 30Kissei Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 07, 2023Kissei Pharmaceutical Co., Ltd. announced that they will report Q2, 2024 results on Nov 07, 2023
お知らせ • Jul 21Kissei Pharmaceutical Co., Ltd. Announces Withdrawal of Application for Marketing Approval for Rovatirelin for the Treatment of Spinocerebellar Degeneration in JapanKissei Pharmaceutical Co., Ltd. announced the withdrawal of application for marketing approval in Japan for Rovatirelin (generic name, development number: KPS-0373), a treatment for spinocerebellar degeneration, in order to consider the future development strategies. Based on the results of two Phase III clinical trials and a combined analysis conducted to date, company determined that Rovatirelin was the first drug which has been verified to be effective to improve ataxia in patients with spinocerebellar degeneration assessed with international SARA score. The company submitted an application for marketing approval on December 22, 2021*. However, Kissei decided to temporarily withdraw the application for marketing approval and discuss the possibility of conducting additional clinical trials with the Pharmaceuticals and Medical Devices Agency (PMDA), because the PMDA has recently expressed its opinion that the marketing approval based on the current clinical trial data would be difficult. The impact of this matter on this fiscal year's business performance is minimal. If any matters requiring disclosure arise in the future, they will be promptly announced.
お知らせ • May 28Kissei Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023Kissei Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on Jul 31, 2023
お知らせ • May 10Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 22, 2023Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 22, 2023.
お知らせ • May 09+ 2 more updatesKissei Pharmaceutical Co., Ltd. (TSE:4547) announces an Equity Buyback for 2,000,000 shares, representing 4.34% for ¥6,000 million.Kissei Pharmaceutical Co., Ltd. (TSE:4547) announces a share repurchase program. Under the program, the company will repurchase up to 2,000,000 shares, representing 4.34% of its share capital, for ¥6,000 million. The company will repurchase its shares in order to implement a flexible capital policy which responds to changes in the business environment, improve capital efficiency, and enhance shareholder returns. The repurchase plan will be valid till March 29, 2024 . As of March 31, 2023, the company had 46,115,567 shares outstanding (excluding treasury shares) and 5,695,618 shares in treasury.
お知らせ • Feb 01+ 1 more updateKissei Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023Kissei Pharmaceutical Co., Ltd. provided dividend guidance for the fiscal year ending March 31, 2023. For the year, the company expects to pay dividend of JPY 40.00 per share against JPY 28.00 per share paid a year ago.
お知らせ • Nov 27Kissei Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Jan 31, 2023Kissei Pharmaceutical Co., Ltd. announced that they will report Q3, 2023 results on Jan 31, 2023
お知らせ • Mar 05Kissei Pharmaceutical Co., Ltd. to Report Fiscal Year 2021 Results on May 11, 2021Kissei Pharmaceutical Co., Ltd. announced that they will report fiscal year 2021 results on May 11, 2021
お知らせ • Nov 29Kissei Pharmaceutical Co., Ltd. to Report Q3, 2021 Results on Feb 01, 2021Kissei Pharmaceutical Co., Ltd. announced that they will report Q3, 2021 results on Feb 01, 2021
お知らせ • Oct 04Kissei Pharmaceutical Co., Ltd. to Report Q2, 2021 Results on Nov 15, 2020Kissei Pharmaceutical Co., Ltd. announced that they will report Q2, 2021 results on Nov 15, 2020